Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during α-interferon treatment

Journal of Hepatology

Volumn 30, Issue 3, 1999, Pages 366-375

  Dalekos, Georgios N ^a   Wedemeyer, Heiner ^a   Obermayer Straub, Petra ^a   Kayser, Anne ^a   Barut, Ayse ^a   Frank, Hannah ^a   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Alpha interferon; Autoimmune hepatitis; Autoimmunity; Chronic hepatitis; Cytochrome P4502D6; Epitope mapping; Hepatitis C virus; LKM antibody

Indexed keywords

ALPHA INTERFERON; AUTOANTIGEN; CYTOCHROME P450 ISOENZYME; EPITOPE;

ADULT; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MAPPING; HEPATITIS C; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033041150     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80092-0     Document Type: Article

References (39)

1. Dalekos GN, Manoussakis MN, Zervou E, Tsianos EV, Moutsopoulos HM. Immunologic and viral markers in anti-HIV negative heroin addicts. Eur J Clin Invest. 23:1993;219-225.
2. Clifford BD, Donahue D, Smith L, Cable E, Lüttig B, Manns M, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology. 21:1995;613-619.
3. Bortoloti F, Vajro P, Balli F, Giacchino R, Crivellaro C, Barbera C, et al. Non-organ specific autoantibodies in children with chronic hepatitis C. J Hepatol. 25:1996;614-620.
4. Seelig R, Renz M, Bünger G, Schröter H, Seelig HP. Anti-LKM-1 antibodies determined by use of recombinant P450 2D6 in ELISA and Western blot and their association with anti-HCV and HCV-RNA. Clin Exp Immunol. 92:1993;373-380.
5. Lenzi M, Johnson PJ, McFarlane IG, Ballardini G, Smith HM, McFarlane BM, et al. Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet. 338:1991;277-280.
6. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest. 88:1991;1370-1378.
7. Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, et al. Chronic active hepatitis associated with anti-liver/kidney microsomes antibody type 1: a second type of"autoimmune" hepatitis. Hepatology. 7:1987;1333-1339.
8. Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA. Antibodies against human cytochrome P-450dbl in autoimmune hepatitis type 2. Proc Natl Acad Sci USA. 85:1988;8256-8260.
9. Guenguen M, Yamamoto AM, Bernard O, Alvarez F. Anti-liver kidney microsomc antibody type 1 recognizes human cytochrome P450 dbl. Biochem Biophys Res Comm. 159:1989;542-547.
10. Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. Major antigen of liver kidney microsomal antibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest. 83:1989;1066-1072.
11. Ma Y, Peakman M, Lobo-Yeo A, Wen L, Lenzi M, Gäken J, et al. Differences in immune recognition of cytochrome P4502D6 by liver kidney microsomal (LKM) antibody in autoimmune hepatitis and chronic hepatitis C virus infection. Clin Exp Immunol. 97:1994;94-99.
12. Yamamoto AM, Cresteil D, Homberg JC, Alvarez F. Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology. 104:1993;1762-1767.
13. Yamamoto AM, Johanet C, Duclos-Vallée J-C, Bustaret FA, Alvarez F, Homberg J-C, et al. A new approach to cytochrome CYP2D6 antibody detection in autoimmune hepatitis type-2 (AIH-2) and chronic hepatitis C virus (HCV) infection: a sensitive and quantitative radioligand assay. Clin Exp Immunol. 108:1997;396-400.
14. Ma Y, Gregorio G, Gäken J, Muratori L, Bianchi FB, Miele-Vergani G, et al. Establishment of a novel radioligand assay using eukaryotically expressed cytochrome P4502D6 for the measurement of liver kidney microsomal type 1 antibody in patients with autoimmune hepatitis and hepatitis C virus infection. J Hepatol. 26:1997;1396-1402.
15. Fattovich G, Betterle C, Brollo L, Pedini B, Giustina G, Realdi G, et al. Autoantibodies during α-interferon therapy for chronic hepatitis B. J Med Virol. 34:1991;132-135.
16. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, Borque MJ, Garcia-Sanchez A, Iglesias R, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology. 108:1995;1770-1777.
17. Dalekos GN, Hatzis J, Tsianos EV. Dermatologic disease during interferon-α therapy for chronic viral hepatitis. [letter] Ann Intern Med. 128:1998;409-410.
18. Dalekos GN, Christodoulou D, Kistis KG, Zervou EK, Hatzis J, Tsianos EV. A prospective evaluation of dermatologic side effects during alpha-interferon therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol. 1998;. (In press).
19. Muratori L, Lenzi M, Cataleta M, Giostra F, Cassani F, Ballardini G, et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol. 21:1994;199-203.
20. Todros L, Saracco G, Durazzo M, Abate ML, Touscoz G, Scaglione L, et al. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver kidney microsomes. Hepatology. 22:1995;1374-1378.
21. Duclos-Vallée, Nishioka M, Hosomi N, Arima K, Leclercq A, Bach J-F, et al. Interferon therapy in LKM1 positive patients with chronic hepatitis C: follow-up by a quantitative radioligand assay for CYP2D6 antibody detection. J Hepatol. 28:1998;965-970.
22. Johnson PJ, McFarlane IG. Convenors, on behalf of the panel. Meeting Report: International autoimmune hepatitis group. Hepatology. 18:1993;998-1005.
23. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. J Hepatol. 1:1981;431-433.
24. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 22:1995;696-699.
25. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol. 74:1993;2391-2399.
26. Gillam EMJ, Guo Z, Martin MV, Jenkins CM, Guenguerich FP. Expression of cytochrome P450 2D6 in E. coli, purification, and spectral and catalytic characterization. Arch Biochem Biophys. 319:1995;540-550.
27. Gebre-Medhin G, Husebye ES, Gustafson J, Winqvist O, Goksoyr A, Rorsman F, et al. Cytochrome P450IA2 and aromatic Lamino acid decarboxylase are hepatic autoantigens in autoimmune polyendocrine syndrome type I. FEBS Lett. 412:1997;439-445.
28. Manns M, Meyer zum Büschenfelde K-H, Slusarczyk J, Dienes HP. Detection of liver-kidney microsomal autoantibodies by radioimmunoassay and their relation to anti-mitochondrial antibodies in inflammatory liver diseases. Clin Exp Immunol. 57:1984;600-608.
29. Rizzeto M, Bianchi FB, Doniach D. Characterization of the microsomal antigen related to a subclass of active chronic hepatitis. Immunology. 26:1974;589-601.
30. Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Büschenfelde K-H. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet. i:1987;292-294.
31. Nishioka M, Morshed SA, Kono K, Himoto T, Parveen S, Arima K, et al. Frequency and significance of antibodies to P450IID6 protein in Japanese patients with chronic hepatitis C. J Hepatol. 26:1997;992-1000.
32. Dusheiko G, Schmilovitzweiss H, Brown D, McOmish F, Yap PL, Sherlock S, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology. 19:1994;13-18.
33. Pawlotsky J-M, Roudot-Thoraval F, Bastie A, Darthuy F, Remire J, Metreau J-M, et al. Factors affecting treatment responses to interferon-α in chronic hepatitis C. J Infect Dis. 174:1996;1-7.
34. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol. 73:1992;673-679.
35. Michitaka K, Durazzo M, Tillman HL, Walker D, Philip T, Manns MP. Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2. Gastroenterology. 106:1994;1603-1610.
36. Obermayer-Straub P, Sugimura T, Braun S, Lütting B, Loges S, Kayser A, et al. Definition of a novel CYP2D6 epitope in autoimmune hepatitis type 2 and in chronic hepatitis C. [abstract] J Hepatol. 28:(Suppl 1):1998;139.
37. Yamamoto AM, Cresteil D, Boniface O, Clerc F, Alvarez F. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). Eur J Immunol. 23:1993;1105-1111.
38. Muratori L, Lenzi M, Ma Y, Cataleta M, Mieli-Vergani G, Bianchi FB. Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease. Gut. 37:1995;406-412.
39. Durazzo M, Philipp T, Van Pelt FNAM, Lüttig B, Borghesio E, Michel G, et al. Heterogeneity of microsomal autoantibodies (LKM) in chronic hepatitis C and D virus infection. Gastroenterology. 108:1995;455-462.